Certified educational activities on Invasive Fungal Infections

New CME/CNE/CPE Activity! Community-Acquired Pneumonia: When to Think Fungus

This CME/CNE/CPE activity will explore community-acquired pneumonia cases, illustrating when to consider coccidioidomycosis, blastomycosis, and histoplasmosis endemic mycoses. The activity will feature use of CDC/MSGERC/CSG algorithms to recognize patients at risk for these infections as well as diagnostic strategies. This activity was developed for a target audience of primary care providers, specialists who prescribe biologics, pulmonologists, as well as urgent care and emergency medicine providers who see patients with community acquired pneumonia.

New! Managing Invasive Candidiasis: Key Strategies to Make a Difference

In this activity, Drs Ostrosky-Zeichner and Peter Pappas illustrate strategies to make a difference in the management of invasive candidiasis. Using an infographic approach to reinforce key concepts, they make a compelling call to action for more state-of-the-art management of this common fungal infection.

COVID-19—Associated Invasive Fungal Infections: Multidisciplinary Management

Accredited for physicians, pharmacists, and nurses (including pharmacotherapy credit for APRNs)

In this multimedia, case-based CE activity, a multidisciplinary panel, including a medical mycologist, infectious diseases pharmacist, pulmonologist, and intensivist, weigh in on challenging COVID-19-associated IFI cases. The activity addresses:

• Candidemia
• COVID-19-associated pulmonary aspergillosis
• Cryptococcosis

COVID-19–Associated Invasive Fungal Infections: Expert Guidance on Cases From the Community Earn up to 1.5 AMA PRA Category 1 Credits(TM).

In this interactive, case-based CME activity, mycology experts Drs George R. Thompson, III; Dimitrios Kontoyiannis; and Minh-Hong Thi Nguyen apply the Care Step Pathway and other tools from this initiative in the management of challenging COVID-19–associated IFI cases submitted by community clinicians. The activity addresses:

• COVID-19—associated pulmonary aspergillosis (CAPA)
• COVID-19–associated mucormycosis
• Coccidioidomycosis reactivation after recovery from COVID-19
• Pharmacologic considerations relevant to COVID-19 patients